Thromb Haemost 1996; 76(01): 034-037
DOI: 10.1055/s-0038-1650518
Original Article
Schattauer GmbH Stuttgart

Influence of Metabolic Control on Thromboxane Biosynthesis and Plasma Plasminogen Activator Inhibitor Type-1 in Non-insulin-dependent Diabetes mellitus

Giovanni Davì
The Department of Internal Medicine, University of Chieti and Palermo, Italy
,
Mario Belvedere
1   The Department of Internal Medicine, University of Palermo, Italy
,
Sergio Vingneri
1   The Department of Internal Medicine, University of Palermo, Italy
,
Isabella Catalano
1   The Department of Internal Medicine, University of Palermo, Italy
,
Carlo Giammarresi
1   The Department of Internal Medicine, University of Palermo, Italy
,
Salvatore Roccaforte
The Department of Internal Medicine, University of Chieti and Palermo, Italy
,
Agostino Consoil
The Department of Internal Medicine, University of Chieti and Palermo, Italy
,
Andrea Mezzetti
The Department of Internal Medicine, University of Chieti and Palermo, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 19. Oktober 1995

Accepted after resubmission01. April 1996

Publikationsdatum:
26. Juli 2018 (online)

Preview

Summary

We have previously shown that tight metabolic control by insulin therapy reduced thromboxane-dependent platelet activation in noninsulin-dependent diabetes mellitus (NIDDM) patients. The present study was undertaken to determine whether a similar effect could be obtained without switching diabetics in secondary failure to insulin treatment. For this purpose, we gave strict diet and exercise advise program and adjusted on a weekly basis the oral antidiabetic therapy (glipizide) that 26 patients with NIDDM had been given over the previous months.

Basal measurements of urinary ll-dehydro-TXB2 and PAI-1 confirmed previous findings of enhanced levels of these parameters in NIDDM patients with macrovascular disease in comparison to age-and sex-matched controls. After 2-6 weeks, 16 patients achieved tight metabolic control associated with significant reduction of both thromboxane biosynthesis and PAI-1 levels; 10 patients remained in poor control and no significant decrease of both parameters was observed.

We conclude that reduction of in-vivo platelet activation and PAI-1 antigen levels after metabolic improvement obtained by frequent reassessment of sulphonylurea therapy together with strict diet and exercise programs may have beneficial effects on the progression of diabetic micro- and macrovascular disease.